Study protocol: computerised cognitive testing in a cohort of people with frontotemporal dementia

Katrina Moore, Rhian S Convery, Jonathan D Rohrer

ABSTRACT

Introduction  The term frontotemporal dementia (FTD) refers to a heterogeneous group of neurodegenerative disorders affecting the frontal and temporal lobes. Cognitively, impairment of executive function and social cognition predominates across the FTD spectrum, although other domains can be affected. Traditionally, cognition is tested through standard ‘pen and paper’ tasks in FTD. However, recent attempts have been made across other neurodegenerative disorders such as Alzheimer’s disease to develop computerised batteries that allow more accurate and sensitive detection of cognitive impairment.

Methods and analysis  This paper describes the development of a novel battery of tests for a tablet computer, particularly focused on FTD. It consists of 12 different tasks which aim to tap into information processing speed, various aspects of executive function, social cognition, semantic knowledge, calculation and visuospatial skills. Future studies will focus on validating the battery in a healthy control cohort, comparing it against a standard ‘pen and paper’ psychometric battery, and finally testing it within an FTD cohort, including those with genetic forms of FTD where we will be able to assess its ability to detect very early cognitive deficits prior to the onset of symptoms.

Ethics and dissemination  Normative data will be produced in the initial validation study (approved by the UCL Ethics Committee, project ID 17691/002) and will be made available online.

INTRODUCTION

Frontotemporal dementia (FTD) is a clinically, pathologically and genetically diverse neurodegenerative disease. It is probably the most common form of dementia in those under 60 years of age and is associated with two main clinical presentations: an impairment in personality and social conduct, known as behavioural variant FTD (bvFTD), and deficits in speech and language, called primary progressive aphasia (PPA). Around a third of FTD is familial, with the majority of autosomal-dominant FTD linked to mutations in three key genes: chromosome 9 open reading frame 72 (C9orf72), progranulin (GRN) and microtubule-associated protein tau (MAPT).

The cognitive deficits found in FTD are commonly in the executive function and social cognition domains for bvFTD, and the language and semantic knowledge domains for those with PPA, although there is often overlap between these disorders. Classically, episodic memory and more posterior cortical functions are spared, particularly in the early stages of the disease. The trajectory of cognitive impairment has now been studied across a number of cohorts, with the earliest change being studied mostly within genetic cohorts where at-risk individuals who are many years from expected symptom onset can be investigated. Deficits across several cognitive tasks have been shown around 5–8 years prior to symptom onset particularly in tests of executive function and social cognition, although the pattern of deficits can differ according to which mutation is carried. However, prior studies have been performed mainly using traditional ‘pen and paper’ tests which may well be limited in their ability to detect subtle changes. Using MRI, neuroanatomical changes can be seen in presymptomatic genetic FTD studies much earlier, potentially over 20 years prior to expected symptom onset, and so there is a need to bridge the gap between the sensitivity of neuroimaging techniques and current cognitive assessments.

Treatment trials in FTD are currently underway, and although many of the planned studies are focused on symptomatic FTD, it is likely that future studies will also include people in the presymptomatic phase of the disease. One of the greatest challenges facing...
trials of this nature is having robust cognitive outcome measures. The Food and Drug Administration have recognised that current assessments are not optimal, highlighting the need for improved cognitive markers as outcome measures for clinical trials, and have encouraged the development of novel approaches to evaluate subtle deficits that may emerge in the presymptomatic stages of dementia. Here we describe the design and protocol of Ignite, a novel computerised cognitive assessment tool designed for FTD. We outline the key objectives for developing a computerised battery and provide an overview of the cognitive domains tested within the battery.

**METHODS AND ANALYSIS**

**Patient and public involvement**

It is standard for traditional cognitive assessments to be performed by trained psychologists in hospital or research settings, which can be both time consuming and costly. On discussion with research participants they describe frequently experiencing high levels of anxiety when attending research visits, particularly in relation to neuropsychological assessment. In presymptomatic FTD studies this can be most prominent in those who have yet to find out their carrier status. In addition, the number of in-person contact days required for a clinical trial can be burdensome and can prevent an individual’s participation. With these considerations in mind, we wanted to design a computerised battery that could be performed by individuals themselves, with the aim of reducing participant anxiety, thus ensuring that their best performance is captured. We therefore initially discussed the development of this battery with a small group of people at-risk of familial FTD to ensure we could maximise the user-friendliness of the battery and reduce the participant burden.

**Objectives for developing a computerised cognitive battery**

Apart from improving the participant experience, we had a number of other objectives for developing the battery as follows.

**Comprehensiveness**

We wanted to develop a set of assessments that could capture an individual’s performance across a number of cognitive domains in a comprehensive manner for FTD. A major drawback of current cognitive assessments is the duration of testing required to get an accurate picture of individual performance, often taking a number of hours. The new battery was designed to be completed in around 30 min or less.

**Increased sensitivity**

Ignite consists mainly of tests which are modifications of existing cognitive tasks. However, each task was modified to shorten the time allowed for completion, with the measurement of reaction times aiming to increase the sensitivity to detect deficits.

**Self-assessment**

A key aim in the development of Ignite was its ability to be performed by individuals on their own, ideally while at home. All assessments were designed to be as intuitive as possible, appearing more like short games than standard cognitive tests, including the use of simple on-screen buttons or swipes to record answers. A challenge in designing tasks with self-assessment in mind is ensuring that participants are motivated to complete the tasks on their own and that they understand what is being asked of them. To assist participants in understanding and remembering task instructions, they are provided with brief written instructions prior to beginning each individual assessment task. Accompanying the written instructions are short videos to ensure participants can clearly visualise and understand what is required of them. In addition, once a task has begun, a prompt of the task instruction is displayed at the top of the screen for the duration of the task. In this way, participants can refresh their memories of the task instructions at any time without having to exit the task. To keep participants motivated and engaged each task was designed to range from 30 to 180 s in duration, with most tasks programmed to time out after 60 s.

**Protocol**

Ignite consists of 12 separate assessments that measure a spectrum of cognitive functions (table 1, figure 1). Each test was included based on knowledge of the deficits seen in FTD, and in particular those domains most likely to be affected presymptomatically. The tests are self-administered in a predetermined order, in an environment familiar to the participant, such as their home. At present, the app is available on the iPad via the App Store, although future iterations will aim to make versions available for other tablets and operating systems.

### Table 1 Summary of tasks within the Ignite protocol

| Cognitive domain                  | Cognitive subdomain   | Task               |
|-----------------------------------|-----------------------|--------------------|
| 1 Executive function and information processing speed | Inhibitory control | Colour Mix         |
| 2                                  |                       | Swipe Out          |
| 3                                  | Cognitive flexibility | Card Sort          |
| 4                                  |                       | Path Finder        |
| 5                                  | Working memory        | Think Back         |
| 6                                  | Decision making       | Balloon Fair       |
| 7                                  | Cognitive timing      | Time Tap           |
| 8 Social cognition                | Emotion processing    | Face Match         |
| 9                                  | Theory of mind        | Mind Reading       |
| 10 Semantic knowledge             |                       | Picture Pair       |
| 11 Arithmetic                     |                       | Sum Up             |
| 12 Visuospatial skills            |                       | Line Judge         |
Executive function

The term executive function describes a number of different aspects of cognition including reasoning, problem solving and planning, commonly related to the workings of the frontal lobe. It consists of a number of different subdomains, which include inhibitory control, cognitive flexibility and working memory. We aimed to design tasks tapping into each of these subdomains as well as decision-making and cognitive timing as previous studies of FTD have shown deficits within all of them, and in particular impairment can be seen presymptomatically across each of the major genetic groups.

Inhibitory control

This subdomain is described as the ability to control one’s attention, behaviour and thoughts to override a strong internal predisposition or external lure. It is abnormal in FTD and relates to the key symptom of disinhibition that forms part of the diagnostic criteria for bvFTD. We included two tasks of inhibitory control.

Colour Mix

In our task, we adapted the classical Stroop task including five different colours: red, blue, green, purple and yellow. The initial two levels of the task test speed of processing. In Level 1, participants are presented with a coloured circle and all five colour names written below. They are asked to match the colour of the circle with the correct colour name from 5. They have 30 s to complete as many as possible (with a maximum of 50 possible trials). In Level 2, participants are presented with the name of a colour and (as with Level 1) the five colour names written below.
They are asked to match the target colour word with the matching word below. They have 30 s to complete as many as possible (with a maximum of 50 possible trials). The next two levels measure inhibitory control. In Level 3, participants are presented with a colour word written in a different colour for example, BLUE written in red ink. They are asked to match the colour of the ink (rather than the name) to one of the five colour names written below. They have 60 s to complete as many as possible (with a maximum of 50 possible trials). Lastly, in Level 4, participants are presented as in Level 3 with a colour word written in a different colour, and have to complete the task as in Level 3, unless a black border appears around the word (as it does on some trials), when they have to match the written word rather than the ink colour (eg, match blue if the word is BLUE written in red ink) to one of the five colour names written below. They have 60 s to complete as many as possible (with a maximum of 50 possible trials).

Path Finder
This task adapts the TMT, asking participants to tap stimuli in sequential order (rather than draw an unbroken line between letters and/or numbers as in the original pen and paper task). Correct sequencing is indicated by the outline of each letter or number changing colour to green. The letter or number changes to red if selected incorrectly. In Level 1, participants are asked to select numbers in the correct order (similar to TMT part A), with a maximum of 60 s to complete the task. In Level 2, participants are asked to alternate between numbers and letters in the correct order (similar to TMT part B), with a maximum of 90 s to complete the task.

Working memory
This subdomain of executive function describes the ability to hold information in mind and mentally work with it. A classic paradigm for assessing working memory is the N-back task, which requires participants to monitor a series of stimuli and respond whenever the stimuli presented matches the properties of the trial presented ‘N’ before it. The task requires the monitoring, updating and manipulation of information displayed to perform the task effectively.

Think Back
There are two levels to our N-back task. Level 1 is a 1-back task and Level 2 is a 2-back task. In Level 1, participants must indicate whether a shape matches the one preceding it. In Level 2, participants must indicate whether a shape matches the shape shown two before it, intended to place greater demand on working memory. An answer is submitted by pressing a ‘yes’ or ‘no’ button. In each level, participants have 60 s to complete as many trials as possible (up to a maximum of 72 trials).

Decision making
For many people with FTD their ability to make decisions is compromised. Several paradigms are employed in assessing decision-making behaviour, often in the form of gambling or risk-taking tasks, such as the Iowa Gambling Task, Cambridge Gambling Task, Game of Dice Task and the Balloon Analogue Risk Task, with people with FTD shown to be impaired on these tests.
money accrued in the temporary bank is lost. Participants have the option to cash in the money accumulated in the temporary bank at any point by clicking the ‘Collect £’ button. After each balloon has popped (money lost) or the money has been collected a new balloon appears. Balloons are differently coloured (green, yellow and blue) with each colour associated with a unique sum (£5, £10, £50, respectively), and a unique popping point (quicker for higher sums). Participants are unaware of the probability of a balloon popping. The aim of the task is to earn as much money as possible. Participants have 90’s to complete the task.

Cognitive timing

The concept of timing is integral to performing many mental processes. Although not well-studied in FTD, one previous study has shown impairment in both externally paced and self-paced finger tapping.

Time Tap

We adapted the task described in Henley et al. to test cognitive timing. A pulsating circle is presented in the middle of the top of the screen and a tone sounds in time to the pulse (at 1500 ms intervals). Participants are asked to use the index finger of their dominant hand to tap in time with the pulsating circle on a second circle presented below. After 30’s the pulsation and tone cease, and participants are instructed to maintain the same tempo for a further 30’s.

Social cognition

Social cognition is the ability to perceive, interpret and generate a response to the intentions, behaviours and feelings of others, and includes a number of subdomains such as emotion recognition and theory of mind. Social cognition impairment occurs early and almost universally in all people with FTD as well as those with other forms of FTD, such as PPA. These deficits include poor recognition of simple emotions in faces, as well as impairment of complex emotion processing, and other tasks of theory of mind. Early deficits have been seen in genetic FTD including those who are presymptomatic.

Face Match

In our task of simple emotion processing, participants are presented with a target basic emotion word (sadness, happiness, anger, fear, disgust, surprise) at the top of the screen alongside four images of eyes in the corners of the screen. Participants are asked to tap all of the faces displaying the target emotion as quickly as possible. There are five correct answers out of each nine presented faces, and participants must press all five within 10’s, or the task moves on to the next set of nine faces. The participants have to complete as many items as possible within 60’s (up to a maximum of six sets of nine faces).

Mind Reading

Our task of complex emotion processing adapts the Reading the Mind in the Eyes test so that participants are presented with a target emotion word in the centre of the screen alongside four images of eyes in the corners of the screen, one of which matches the emotion. Participants are asked to select the image which best matches the target emotion word, completing as many as possible within 90’s (up to a maximum of 20 words).

Semantic knowledge

Impairment of semantic knowledge is characteristic of the semantic variant of PPA but is seen in other forms of FTD, and has been shown to occur presymptomatically, particularly in those with MAPT mutations.

Picture Pair

Our task uses stimuli from the modified version of the Camel and Cactus task that we have previously described as detecting early semantic deficits in genetic FTD. The participant has to match a target picture with a semantically linked matching picture from a choice of four for example, matching Camel with Cactus rather than a tree, sunflower or rose. The participants have to answer as many questions as possible in 120’s (with a maximum of 25 questions).

Arithmetic

Calculation abilities have been shown to be highly dependent on left parietal lobe function. Although initial studies focused on anterior involvement of the frontal and temporal lobes in FTD, more recent studies have shown that some forms of FTD can have more posterior cortical atrophy, particularly those with GRN mutations and C9orf72 expansions, including presymptomatically. Dyscalculia has been reported in both of these groups. Although deficits are generally not limited to one form of mental arithmetic, one study has shown deficits specifically in multiplication in amyotrophic lateral sclerosis.

Sum Up

Our task includes additions, subtractions, multiplications and divisions, with participants presented with the sum and four possible answers, and a time limit of 10’s for completion of each sum. The participants have to answer as many questions as possible within 60’s (with a maximum of 48 sums, 12 of each type).

Visuospatial skills

Visuospatial processing is classically associated with right parietal lobe function. As mentioned above, more posterior cortical atrophy, including involvement of the right parietal lobe has been seen in genetic FTD. Given this finding, it is unsurprising that several studies have highlighted impairments of visuospatial skills in both GRN mutation carriers and C9orf72 expansion carriers.

Line Judge

Judgement of line orientation is a standard measure of visuospatial skills, testing an individual’s ability to match the angle and orientation of lines in space, with
deficits seen in forms of dementia such as Alzheimer’s diseases and Dementia with Lewy Bodies which are usually associated with parietal atrophy.62 63

In our task, participants are presented with pairs of angled lines and are asked to match the target pair of lines to a set of 11 lines arranged in a semicircle and numbered 1 to 11. Participants press the correct numbers that correspond to the line pair. The participants have to answer as many questions as possible within a 90 s time-frame (up to a maximum of 15 pairs).

Ethics and dissemination

Ignite is a novel computerised battery of assessments for the detection of cognitive changes in FTD. It includes tasks of information processing speed, executive function, social cognition, semantic knowledge, arithmetic and visuospatial skills. It potentially may be sensitive enough to detect early (and presymptomatic) deficits within an at-risk genetic cohort. Ignite will be initially validated in a healthy control cohort and compared against a standard set of ‘pen and paper’ psychometric tasks, including assessment of test–retest reliability. Normative data will be produced in this initial validation study (approved by the UCL Ethics Committee, project ID 17691/002) and will be made available online. The battery will then be tested within an FTD cohort such as GENFI (www.genfi.org11), where it would be possible to assess both presymptomatic and symptomatic people with FTD. In the future, we would also hope to be able to compare Ignite with other emerging computerised batteries aimed specifically at FTD, such as those being developed as part of the ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD: www.allftd.org) study. The final goal of the Ignite study will be to develop a set of validated tasks which are able to track disease progression in FTD, specifically in the presymptomatic and very early symptomatic phase of the disease, and therefore have the potential to be employed in clinical trials as a cognitive outcome measure.

Acknowledgements

We thank the research participants at the Dementia Research Centre for their contribution to the development of Ignite.

Contributors

KM, RSC and JR wrote the manuscript. All authors have read and approved the manuscript.

Funding

The pilot version of the app was developed through an Alzheimer’s Society PhD studentship (for KKM) awarded to JDR (AS-PhD-2015-005), with further development funded by a Frontotemporal Dementia Research Studentship in Memory of David Blechner awarded through The National Brain Appeal (RCN 290173) to RSC. JDR has received funding from an MRC Clinician Scientist Fellowship (MR/M008525/1), an NIHR Rare Disease Translational Research Collaboration (BRC149/NS/MH) and the Brain Research UK Miriam Marks Senior Fellowship; his work is also supported by the MRC UK GENFI grant (MR/M023664/1), the Bluefield Project and the JPNF GENFI-PROX grant (2019-02248). None of the funding bodies had any direct input into the app development.

Competing interests

KM is now an employee of Ionis Pharmaceuticals. JR has served on medical advisory boards or provided consultancy for Alector, Arkuda Therapeutics, Wave Life Sciences, Prevail Therapeutics, UCB, AC Immune, Astex Pharmaceuticals, Biogen, Takeda and Eisai.

Patient and public involvement

Patients and/or the public were involved in the design, or conduct, or reporting or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication

Not applicable.

Provenance and peer review

Not commissioned; externally peer reviewed.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs

Katrina Moore http://orcid.org/0000-0002-4458-8390
Rhian S Convery http://orcid.org/0000-0002-9477-1812
Jonathan D Rohrer http://orcid.org/0000-0002-6155-8417

REFERENCES

1. Warren JD, Rohrer JD, Rossor MN. Clinical review. frontotemporal dementia. BMJ 2013;347:f4827.
2. Rohrer JD, Guarrojo R, Vandrovcova J, et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology 2009;73:1451–6.
3. Grossman M. Frontotemporal dementia: a review. J Int Neuropsychol Soc 2002;8:566–83.
4. Harciarek M, Jodzio K. Neuropsychological differences between frontotemporal dementia and Alzheimer’s disease: a review. Neuropsychol Rev 2005;15:131–45.
5. Harciarek M, Cosentino S. Language, executive function and social cognition in the diagnosis of frontotemporal dementia syndromes. Int Rev Psychiatry 2013;25:178–96.
6. Woollacott IOC, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. J Neurochem 2016;138 Suppl 1:3–1.
7. Doleon J, Miller BL. Frontotemporal dementia. Handb Clin Neurol 2018;148:409–30.
8. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006–14.
9. Goshchwind DH, Robidoux J, Alarcón M, et al. Dementia and neurodevelopmental predisposition: cognitive dysfunction in presymptomatic subjects precedes dementia by decades in frontotemporal dementia. Ann Neurol 2001;50:741–6.
10. Hallam BJ, Jacova C, Hsiung G-YR, et al. Early neuropsychological characteristics of progranulin mutation carriers. J Int Neuropsychol Soc 2014;20:694–703.
11. Rohrer JD, Nicholas JM, Cash DM, et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the genetic frontotemporal dementia initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol 2015;14:253–62.
12. Jiskoot LC, Doper EGP, Heijer Tden, et al. Presymptomatic cognitive decline in familial frontotemporal dementia: a longitudinal study. Neurology 2016;87:384–91.
13. Papma JM, Jiskoot LC, Panman JL, et al. Cognition and gray and white matter characteristics of presymptomatic C9orf72 repeat expansion. Neurology 2017;89:1256–64.
14. Suhonen N-M, Haapalää RM, Korhonen V, et al. Neuropsychological profile in the C9orf72 associated behavioral variant frontotemporal dementia. J Alzheimers Dis 2017;58:479–89.
15. Jiskoot LC, Panman JL, van Asseldonk L, et al. Longitudinal cognitive biomarkers predicting symptom onset in presymptomatic frontotemporal dementia. J Neurol 2018;265:1381–92.
16. Sabbagh MN, Hendrix S, Harrison JE. FDA position statement “Early Alzheimer’s disease: Developing drugs for treatment, Guidance for Industry”. In: Alzheimer’s & dementia. New York, N. Y., 2011;24:59–67.
17. Strenziok M, Pulasaki S, Krueger F, et al. Regional brain atrophy and neurodevelopmental predisposition: cognitive dysfunction in familial frontotemporal dementia in presymptomatic subjects precedes dementia by decades in frontotemporal dementia. J Neurochem 2017;148:409–30.
18. Collins A, Koechlin E. Reasoning, learning, and creativity: frontal lobe function and human decision-making. PLOS Biol 2012;10:e1001293.
19. Diamond A. Executive functions. Annu Rev Psychol 2013;64:135–68.
20. Stretenk M, Pulasaki S, Krueger F, et al. Regional brain atrophy and impaired decision making on the balloon analog risk task in behavioral variant frontotemporal dementia. Cogn Behav Neurol 2011;24:59–67.
21. Maras F, Torralba T, Ibáñez A, et al. Decision-making in frontotemporal dementia: clinical, theoretical and legal implications. Dement Geriatr Cogn Disord 2011;32:11–17.
22 Henley SMD, Downey LE, Nicholas JM, et al. Degradation of cognitive timing mechanisms in behavioural variant frontotemporal dementia. *Neuropsychologia* 2014;65:88–101.

23 Staffaroni AM, Bajorek L, Cesaletto KB, et al. Assessment of executive function in patients with familial and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint. *Alzheimers Dement* 2020;16:11–21.

24 Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* 2011;134:2456–77.

25 Stuss DT, Levine B, Alexander MP, et al. Wisconsin card sorting test performance in patients with frontal focal and posterior brain damage: effects of lesion location and test structure on separable cognitive processes. *Neuropsychologia* 1994;32:388–402.

26 Delis D, Kaplan E, J.H, K. The Delis-Kaplan Executive Function System: Examiner’s Manual. San Andonio The Psychological Corporation; 2001.

27 Rohrer JD, Warren JD, Omar R, et al. Parietal lobe deficits in frontotemporal lobar degeneration caused by a mutation in the progranulin gene. *Arch Neurol* 2008;65:506–13.

28 Barandiaran M, Estanga A, Moreno F, et al. Neuropsychological features of atypical c.709-1G>A progranulin mutation carriers. *J Int Neuropsychol Soc* 2012;18:1086–90.

29 Lange F, Brückner C, Knebel A, et al. Executive dysfunction in Parkinson’s disease: a meta-analysis on the Wisconsin card sorting test literature. *Neurosci Biobehav Rev* 2018;39:38–56.

30 Baddley AD, Hitch GJ. Developments in the concept of working memory. *Psychol Rev* 1991;98:530–40.

31 Owen AM, McMillan KM, Laird AR, et al. N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies. *Hum Brain Mapp* 2005;25:46–59.

32 Stuss DT, Levine B, Alexander MP, et al. Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 expansions. *Amyotroph Lateral Scler Frontotemporal Degen* 2015;16:497–505.

33 Bechara A, Van Der Linden M. Theory of mind in patients with frontal variant frontotemporal dementia and Alzheimer’s disease: theoretical and practical implications. *Brain* 2002;125:752–64.

34 Rogers RD, Owen AM, McMillan KM, Laird AR, et al. The NimStim set of facial expressions: judgments from untrained research participants. *Psychiatry Res* 2009;168:242–9.

35 Brand M, Fujiwara E, Borsutsky S, et al. Executive dysfunction in frontotemporal lobar degeneration caused by a mutation in the progranulin gene. *Arch Neurol* 2008;65:506–13.

36 Salimi S, Irish M, Foxe D. Can visuospatial measures improve performance in patients with corticobasal syndrome? *Sci Rep* 2016;6:22913.

37 Moore K, Convery R, Bocchetta M. A modified camel and cactus test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. *Appl Neuropsychol Adult* 2020;1–8.

38 Moreau D, Innes JA, Cook IA, et al. Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 expansions. *Amyotroph Lateral Scler Frontotemporal Degen* 2015;16:497–505.

39 Moore K, et al. BMJ Open 2022;12:e055211. doi:10.1136/bmjopen-2021-055211